What's Happening?
Andelyn Biosciences has introduced the LVV Curator® Platform, a new standardized solution for lentiviral vector (LVV) manufacturing. This platform is designed to streamline the transition from research-grade to GMP-compliant manufacturing for cell therapy
developers. By leveraging Andelyn's proven Curator® viral vector platform methodology, the LVV Curator Platform aims to reduce development time and cost while ensuring high productivity and purity. The platform incorporates Optimization-by-Design™ principles and uses the clinically validated HEK293 cell line to support regulatory confidence and streamline development activities.
Why It's Important?
The launch of the LVV Curator Platform is a significant advancement in the field of cell therapy development. It addresses the critical challenge of moving from research-grade production to robust, GMP-compliant manufacturing, which is essential for clinical and commercial success. By providing a predefined, scalable framework, Andelyn Biosciences helps developers minimize risks and enhance process robustness. This platform supports the development of next-generation gene therapies, potentially accelerating the availability of innovative treatments for patients and advancing the field of regenerative medicine.
